AptarGroup Inc. shared a presentation for the Bank of America 2026 Global Agriculture and Materials Conference outlining its business across Pharma, Beauty and Closures, with reported 2025 sales mix including Pharma at 46 percent, Beauty at 35 percent and Closures at 19 percent. The presentation highlighted Aptar’s proprietary drug delivery and dispensing technologies, an intellectual property portfolio of more than 7,300 granted or pending patents, and R&D spending of about 3 percent of sales in fiscal 2025. The materials provided segment details including Aptar Pharma fiscal 2025 revenue of $1.7 billion with a 35.0 percent adjusted EBITDA margin, and Aptar Beauty fiscal 2025 revenue of $1.3 billion with a 12.1 percent adjusted EBITDA margin. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.